FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2550204099> ?p ?o ?g. }

• W2550204099 abstract "Purpose: To determine the principal toxicities, characterize the pharmacokinetics (PKs) and pharmacodynamics (PDs) of temozolomide (TMZ) on a daily-for-5days schedule, and recommend a dose for subsequent disease-directed studies in both minimally pretreated (MP) and heavily pretreated (HP) patients. Patients and Methods: Patients received TMZ as a single oral dose daily for 5 consecutive days every 28 days. TMZ doses were escalated from 100 to 150, and 150 to 200 mg/m2/d in separate cohorts of MP and HP patients. PK plasma was sampled on days 1 and 5. TMZ concentrations were analyzed and pertinent PK parameters were related to the principal toxicities of TMZ in PD analyses. Results: Twenty-four patients were treated with 85 courses of TMZ. Thrombocytopenia and neutropenia were the principal dose-limiting toxicities (DLTs) of TMZ on this schedule. The cumulative rate of severe myelosuppressive effects was unacceptably high at TMZ doses exceeding 150 mg/m 2 /d in both MP and HP patients. TMZ was absorbed rapidly with maximum concentrations achieved in 0.90 hours, on average, and elimination was rapid, with a half-life and systemic clearance rate (ClS/F) averaging 1.8 hours and 115 mL/min/m2, respectively. When clearance was normalized to body-surface area (BSA), interpatient variability in ClS/F was reduced from 20% to 13% on day 1 and from 16% to 10% on day 5. Patients who experienced DLT had significantly higher maximum drug concentration (median 16 v 9.5 mg/mL, P 5 .0084) and area under the concentration-time curve (median 36 v 23 mg-h/mL, P 5 .0019) values on day 5. Conclusion: Prior myelosuppressive therapy was not a determinant of toxicity. TMZ 150 mg/m2/d administered as a single oral dose daily for 5 days every 4 weeks is well tolerated by MP and HP patients, with higher doses resulting in unacceptably high rates of severe hematologic toxicity. TMZ doses should be individualized according to BSA rather than use of a prespecified oral dose for all individuals. TMZ is an optimal agent to develop in combination with other cytotoxic, biologic, and targeted therapeutics for patients with relevant malignancies. J Clin Oncol 17:2604-2613. r 1999 by American Society of Clinical Oncology." @default.
• W2550204099 created "2016-11-30" @default.
• W2550204099 creator A5000168753 @default.
• W2550204099 creator A5002037553 @default.
• W2550204099 creator A5005738281 @default.
• W2550204099 creator A5010851480 @default.
• W2550204099 creator A5011905014 @default.
• W2550204099 creator A5039061943 @default.
• W2550204099 creator A5048907012 @default.
• W2550204099 creator A5069338608 @default.
• W2550204099 creator A5071938679 @default.
• W2550204099 creator A5075567012 @default.
• W2550204099 creator A5077260725 @default.
• W2550204099 creator A5080900202 @default.
• W2550204099 date "1999-01-01" @default.
• W2550204099 modified "2023-09-27" @default.
• W2550204099 title "Phase I a nd P harmacokinetic S tudy o f T emozolomide on a D aily-for-5-Days S chedule i n P atients With A dvanced S olid M alignancies" @default.
• W2550204099 cites W1525505117 @default.
• W2550204099 cites W1550111394 @default.
• W2550204099 cites W1575812451 @default.
• W2550204099 cites W1576871010 @default.
• W2550204099 cites W1602252590 @default.
• W2550204099 cites W1674116136 @default.
• W2550204099 cites W1835101589 @default.
• W2550204099 cites W1861898234 @default.
• W2550204099 cites W1972180573 @default.
• W2550204099 cites W1980195588 @default.
• W2550204099 cites W1990159395 @default.
• W2550204099 cites W2032064524 @default.
• W2550204099 cites W2042094420 @default.
• W2550204099 cites W2075034527 @default.
• W2550204099 cites W2076176285 @default.
• W2550204099 cites W2079203845 @default.
• W2550204099 cites W2079786467 @default.
• W2550204099 cites W2109549713 @default.
• W2550204099 cites W2113895505 @default.
• W2550204099 cites W2114355175 @default.
• W2550204099 cites W2129160559 @default.
• W2550204099 cites W2141521501 @default.
• W2550204099 cites W2167008855 @default.
• W2550204099 cites W235444781 @default.
• W2550204099 cites W2407104316 @default.
• W2550204099 hasPublicationYear "1999" @default.
• W2550204099 type Work @default.
• W2550204099 sameAs 2550204099 @default.
• W2550204099 citedByCount "0" @default.
• W2550204099 crossrefType "journal-article" @default.
• W2550204099 hasAuthorship W2550204099A5000168753 @default.
• W2550204099 hasAuthorship W2550204099A5002037553 @default.
• W2550204099 hasAuthorship W2550204099A5005738281 @default.
• W2550204099 hasAuthorship W2550204099A5010851480 @default.
• W2550204099 hasAuthorship W2550204099A5011905014 @default.
• W2550204099 hasAuthorship W2550204099A5039061943 @default.
• W2550204099 hasAuthorship W2550204099A5048907012 @default.
• W2550204099 hasAuthorship W2550204099A5069338608 @default.
• W2550204099 hasAuthorship W2550204099A5071938679 @default.
• W2550204099 hasAuthorship W2550204099A5075567012 @default.
• W2550204099 hasAuthorship W2550204099A5077260725 @default.
• W2550204099 hasAuthorship W2550204099A5080900202 @default.
• W2550204099 hasConcept C111113717 @default.
• W2550204099 hasConcept C112705442 @default.
• W2550204099 hasConcept C126322002 @default.
• W2550204099 hasConcept C126894567 @default.
• W2550204099 hasConcept C127413603 @default.
• W2550204099 hasConcept C188198153 @default.
• W2550204099 hasConcept C2776694085 @default.
• W2550204099 hasConcept C2777063308 @default.
• W2550204099 hasConcept C2777389519 @default.
• W2550204099 hasConcept C2777501473 @default.
• W2550204099 hasConcept C71924100 @default.
• W2550204099 hasConcept C78519656 @default.
• W2550204099 hasConcept C98274493 @default.
• W2550204099 hasConceptScore W2550204099C111113717 @default.
• W2550204099 hasConceptScore W2550204099C112705442 @default.
• W2550204099 hasConceptScore W2550204099C126322002 @default.
• W2550204099 hasConceptScore W2550204099C126894567 @default.
• W2550204099 hasConceptScore W2550204099C127413603 @default.
• W2550204099 hasConceptScore W2550204099C188198153 @default.
• W2550204099 hasConceptScore W2550204099C2776694085 @default.
• W2550204099 hasConceptScore W2550204099C2777063308 @default.
• W2550204099 hasConceptScore W2550204099C2777389519 @default.
• W2550204099 hasConceptScore W2550204099C2777501473 @default.
• W2550204099 hasConceptScore W2550204099C71924100 @default.
• W2550204099 hasConceptScore W2550204099C78519656 @default.
• W2550204099 hasConceptScore W2550204099C98274493 @default.
• W2550204099 hasLocation W25502040991 @default.
• W2550204099 hasOpenAccess W2550204099 @default.
• W2550204099 hasPrimaryLocation W25502040991 @default.
• W2550204099 hasRelatedWork W2015755263 @default.
• W2550204099 hasRelatedWork W2039363762 @default.
• W2550204099 hasRelatedWork W2056110230 @default.
• W2550204099 hasRelatedWork W2056283760 @default.
• W2550204099 hasRelatedWork W2104850879 @default.
• W2550204099 hasRelatedWork W2136158663 @default.
• W2550204099 hasRelatedWork W2267482046 @default.
• W2550204099 hasRelatedWork W2274349756 @default.
• W2550204099 hasRelatedWork W2287961714 @default.
• W2550204099 hasRelatedWork W2410717561 @default.
• W2550204099 hasRelatedWork W2475755925 @default.
• W2550204099 hasRelatedWork W2549887646 @default.

• next